Researchers at the, Riverside, backed by a substantial NIH grant, are pioneering a study on the unique immune responses to ...

As research continues, those involved say this would be a game changer, especially for patients with very limited options.

Despite long COVID’s vast reach, and more than $1 billion spent on research, no new treatments have been brought to market.

The National Medical Commission (NMC) has not yet taken any action against 198 medical colleges that were found to be not ...

The annual 5-day intense discussions of the World Economic Forum (WEF) delving into global and regional challenges ended on ...

BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...

A decades-old NHTSA vehicle flammability standard leads to the use of cancer-causing flame retardants in cars. These ...

LEQEMBI ® [ (lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer's disease (AD). Treatment with LEQEMBI should be initiated in patients with mild ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...

To deliver on pledges from the Trump administration to make America healthy again, policymakers will need to close gaps in ...

UnitedHealth has revealed that 190 million Americans had their personal and healthcare data stolen in the Change Healthcare ...